Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo

Stem Cells

Volumn 30, Issue 2, 2012, Pages 266-279

  Xu, Song ^a,b,c   Menu, Eline ^b   De Becker, Ann ^a,b   Van Camp, Ben ^b   Vanderkerken, Karin ^b   Van Riet, Ivan ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemokine; Mesenchymal stromal cells; Microenvironment; Multiple myeloma

Indexed keywords

BORTEZOMIB; CASPASE 3; CYCLIN D2; DICKKOPF 1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN BCL XL; PROTEIN KINASE B; VASCULOTROPIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW; CELL CONTACT; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES; CHEMOKINES, CC; CHEMOTAXIS; COCULTURE TECHNIQUES; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PRIMARY CELL CULTURE; RECEPTORS, CCR;

MURINAE; MUS;

EID: 84856100197     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.787     Document Type: Article

References (81)

1. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004;22:1338-1345. (Pubitemid 39636409)
2. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003;102:1548-1549.
3. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235-242. (Pubitemid 30340601)
4. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-4295. (Pubitemid 35471185)
5. Campagnoli C, Roberts IA, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396-2402.
6. Väänänen HK. Mesenchymal stem cells. Ann Med 2005;37:469-479. (Pubitemid 41693577)
7. Da Silva ML, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-2213. (Pubitemid 43960310)
8. Barrilleaux B, Phinney DG, Prockop DJ et al. Review: Ex vivo engineering of living tissues with adult stem cells. Tissue Eng 2006;12:3007-3019. (Pubitemid 44846407)
9. Dazzi F, Ramasamy R, Glennie S et al. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006;20:161-171.
10. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397. (Pubitemid 43847148)
11. Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando) 2008;22:262-273.
12. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-1761. (Pubitemid 41208591)
13. Kon E, Muraglia A, Corsi A et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res 2000;49:328-337. (Pubitemid 30030478)
14. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318. (Pubitemid 40524615)
15. Hata N, Shinojima N, Gumin J et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 2010;66:144-156.
16. Dwyer RM, Potter-Beirne SM, Harrington KA et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007;13:5020-5027. (Pubitemid 47502066)
17. Ho IA, Chan KY, Ng WH et al. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 2009;27:1366-1375.
18. Kidd S, Caldwell L, Dietrich M et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010;12:615-625.
19. Klopp AH, Gupta A, Spaeth E et al. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth? Stem Cells 201129;11-19.
20. Khakoo AY, Pati S, Anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006;203:1235-1247. (Pubitemid 43736593)
21. Secchiero P, Zorzet S, Tripodo C et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One 2010;5:e11140.
22. Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 1999;55:663-667. (Pubitemid 29221598)
23. Lu YR, Yuan Y, Wang XJ et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008;7:245-251. (Pubitemid 351590431)
24. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563. (Pubitemid 47525152)
25. Bian ZY, Fan QM, Li G et al. Human mesenchymal stem cells promote growth of osteosarcoma: Involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci 2010;101:2554-2560.
26. Yu JM, Jun ES, Bae YC et al. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008;17:463-473. (Pubitemid 351948199)
27. Shinagawa K, Kitadai Y, Tanaka M et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010;127:2323-2333.
28. Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822-4827.
29. Ren C, Kumar S, Chanda D et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008;15:1446-1453.
30. Ramasamy R, Lam EW, Soeiro I et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia 2007;21:304-310. (Pubitemid 46158124)
31. Li L, Tian H, Yue W et al. Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vitro. J Cell Physiol 2011;226:1860-1867.
32. Kidd S, Spaeth E, Klopp A et al. The (in) auspicious role of mesenchymal stromal cells in cancer: Be it friend or foe. Cytotherapy 2008;10:657-667.
33. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-887. (Pubitemid 38368839)
34. Mitsiades CS, McMillin DW, Klippel S et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007;21:1007-1034. (Pubitemid 350051349)
35. Basak GW, Srivastava AS, Malhotra R et al. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009;10:345-346.
36. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
37. Radl J, De Glopper ED, Schuit HR et al. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979;122:609-613. (Pubitemid 9089221)
38. Vanderkerken K, De Raeve H, Goes E et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76:451-460. (Pubitemid 27331209)
39. Matsuoka Y, Moore GE, Yagi Y et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967;125:1246-1250.
40. Van Riet I, De Greef C, Aharchi F et al. Establishment and characterization of a human stroma-dependent multiple myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 1997;11:284-293. (Pubitemid 27085175)
41. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
42. De Becker A, Van Hummelen P, Bakkus M et al. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 2007;92:440-449. (Pubitemid 350144289)
43. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: Isolation, in vitro expansion, and characterization. Br J Haematol 2003;123:702-711. (Pubitemid 37468069)
44. Xu S, De Becker A, Van Camp B et al. An improved harvest and in vitro expansion protocol for murine bone marrow derived mesenchymal stem cells. J Biomed Biotechnol 2010;2010:105940.
45. Menu E, Kooijman R, Van Valckenborgh E et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, Vegf secretion and proliferation of multiple myeloma cells: Study in the 5T33MM model. Br J Cancer 2004;90:1076-1083. (Pubitemid 38495831)
46. Menu E, Garcia J, Huang X et al. A novel therapeutic combination using PD 0332991 and bortezomib: Study in the 5T33MM myeloma model. Cancer Res 2008;68:5519-5523.
47. Gunn WG, Conley A, Deininger L et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006;2:986-991. (Pubitemid 44464731)
48. Uchiyama H, Barut BA, Mohrbacher AF et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-3720. (Pubitemid 24006055)
49. Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001;15:1950-1961. (Pubitemid 33115003)
50. Kim SM, Lim JY, Park SI et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-9623.
51. Loebinger MR, Eddaoudi A, Davies D et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009;69:4134-4142.
52. Sonabend AM, Ulasov IV, Tyler MA et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26:831-841.
53. Ren C, Kumar S, Chanda D et al. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008;26:2332-2338.
54. Kim SM, Oh JH, Park SA et al. Irradiation enhances the tumor tropism and therapeutic potential of TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010;28:2217-2228.
55. Rosová I, Dao M, Capoccia B et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008;26:2173-2182.
56. Huang J, Zhang Z, Guo J et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010;106:1753-1762.
57. Zabel BA, Agace WW, Campbell JJ et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999;190:1241-1256.
58. Papadakis KA, Prehn J, Moreno ST et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001;121:246-254. (Pubitemid 32729371)
59. Amersi FF, Terando AM, Goto Y et al. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008;14:638-645. (Pubitemid 351231142)
60. Singh S, Singh UP, Stiles JK et al. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res 2004;10:8743-8750. (Pubitemid 40053444)
61. Johnson EL, Singh R, Singh S et al. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol 2010;8:62.
62. Johnson-Holiday C, Singh R, Johnson E et al. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol 2011;38:1279-1285.
63. Binger T, Stich S, Andreas K et al. Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25. Exp Cell Res 2009;315:1468-1479.
64. Stich S, Loch A, Leinhase I et al. Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. Eur J Cell Biol 2008;87:365-376.
65. Chamberlain G, Wright K, Rot A et al. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: Comparison with human. PLoS One 2008;3:e2934.
66. Wang X, Zhang Z, Yao C. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res 2010;34:1325-1329.
67. Fuhler GM, Baanstra M, Chesik D et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 2010;316:1816-1828.
68. Sanz-Rodríguez F, Ruiz-Velasco N, Pascual-Salcedo D et al. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 1999;107:825-834. (Pubitemid 30020157)
69. Michigami T, Shimizu N, Williams PJ et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)-beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953-1960. (Pubitemid 30661083)
70. Mori Y, Shimizu N, Dallas M et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004;104:2149-2154. (Pubitemid 39297870)
71. Meirelles Lda S, Fontes AM, Covas DT et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009;20:419-427.
72. Arnulf B, Lecourt S, Soulier J et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007;21:158-163. (Pubitemid 44921847)
73. Corre J, Mahtouk K, Attal M et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007;21:1079-1088. (Pubitemid 46672085)
74. Garayoa M, Garcia JL, Santamaria C et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009;23:1515-1527.
75. Todoerti K, Lisignoli G, Storti P et al. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 2010;38:141-153.
76. Li B, Fu J, Chen P et al. Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch Med Res 2010;41:623-633.
77. Wang X, Zhang Z, Yao C. Angiogenic activity of mesenchymal stem cells in multiple myeloma. Cancer Invest 2011;29:37-41.
78. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000;60:6763-6770.
79. Ogata A, Chauhan D, Teoh G et al. IL-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activated protein kinase cascade. J Immunol 1997;159:2212-2220.
80. Li X, Ling W, Pennisi A et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells 2011;29:263-273.
81. Ning H, Yang F, Jiang M et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 2008;22:593-599. (Pubitemid 351386730)